Whole body studies using long-lived growth hormone receptor gene disrupted or knock out (GHR-KO) mice report global GH resistance, increased insulin sensitivity, reduced insulin-like growth factor 1 (IGF-1), and cognitive retention in old-age, however, little is known about the neurobiological status of these mice. The aim of this study was to determine if glutamatergic and inflammatory markers that are altered in aging and/or age-related diseases and disorders, are preserved in mice that experience increased healthspan. We examined messenger ribonucleic acid (mRNA) expression levels in the brain of 4-6, 8-10, and 20-22 month GHR-KO and normal aging control mice. In the hippocampus, glutamate transporter 1 (GLT-1) and anti-inflammatory nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB)-p50 were elevated in 8-10 month GHR-KO mice compared to age-matched controls. In the hypothalamus, NFκB-p50, NFκB-p65, IGF-1 receptor (IGF-1R), glutamate/aspartate transporter (GLAST), and 2-amino-3-(5-methyl-3-oxo 2,3-dihydro-1,2 oxazol-4-yl) propanoic acid receptor subunit 1 (GluA1) were elevated in 8-10 and/or 20-22 month GHR-KO mice when comparing genotypes. Finally, interleukin 1-beta (IL-1β) mRNA was reduced in 4-6 and/or 8-10 month GHR-KO mice compared to normal littermates in all brain areas examined. These data support the importance of decreased brain inflammation in early adulthood and maintained homeostasis of the glutamatergic and inflammatory systems in extended longevity.
Introduction
Specific areas of the brain are essential for several processes that play a key role in extended longevity, including hippocampus (cognition), hypothalamus (insulin-glucose homeostasis and energy expenditure), and striatum (motor learning and movements). These regions are interconnected through neuronal pathways, have an extensive glutamatergic component, and their dysfunction can lead to accelerated aging as well as several age-related diseases and disorders including dementia, Alzheimer's disease, diabetes, and Parkinson's diseases [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Many of these illnesses occur as the result of a slow build-up of harmful material that occurs over several years.
For instance, there is a build-up of plaques, tangles, and inflammation coupled with neurodegeneration in the glutamate rich hippocampal region in Alzheimer's disease. Diabetes may be the result of chronic inflammation, likely in the hypothalamus, which is responsible for insulin-glucose homeostasis and has an abundance of glucose-sensing neurons that are primarily glutamatergic in nature 12, 14, 15 . Taken together these data support the necessity for preservation of neuronal function in key brain areas resulting in increased healthspan.
Two of the main interrelated systems thought to be involved in age-and metabolic-related cognitive disorders are the glutamatergic and inflammatory systems. Glutamate (Glu) is the predominant excitatory neurotransmitter in the mammalian central nervous system and its dysregulation has been associated with decreased cognition, increased inflammation, and several age-related neurodegenerative diseases such as Alzheimer's and Parkinson's diseases 1, 3, 4, 10, [16] [17] [18] [19] [20] [21] [22] .
In the brain, glial cells, composed of astrocytes and microglia, are the primary contributors to clearance of Glu from the extracellular space through surface expression of excitatory amino acid transporters (EAAT). One such transporter, GLT-1 in rodents (EAAT2 in humans), is responsible for up to 90% of Glu clearance from the extracellular space in the brain, and has been shown to decrease in abundance and function with age, leading to increased extracellular Glu and excitotoxicity 19 . Additionally, glia are the main producers of inflammatory (pro-and antiinflammatory) mediators in the brain and play an important role in innate immunity. For instance, activated microglia enhance production of inflammatory cytokines, such as IL-1β [23] [24] [25] , and decrease anti-inflammatory cytokines, such as IκB kinase β (IKKβ), NFκB-p50, NFκB-p65 26,27 .
During aging, microglia have an increased inflammatory response and may contribute to the onset of chronic neurodegenerative diseases 27-29 . Furthermore, IGF-1 plays a role in information processing in the brain that may be independent of circulating IGF-1 30 . These data support an interrelated mechanism whereby increased neuronal extracellular Glu and elevated neuroinflammation may be responsible for the cognitive decline associated with aging.
The aim of this study was to determine if glutamatergic and inflammatory markers that are known to be altered with normal aging and/or age-related diseases and disorders are preserved in mice that experience successful aging. We used long-lived GHR-KO mice that live 35-70% longer than their normal littermates. GHR-KO mice are GH resistant with low levels of IGF-1 (which may offer protection for disease associated neuronal loss 31 and be involved in extended life-span 32 ), and have improved insulin signaling, decreased pro-inflammatory and increased antiinflammatory activity in the periphery, and decreased oxygen consumption and energy cost of locomotor activity, all of which may contribute to their increased longevity [33] [34] [35] [36] [37] . Additionally, GHR-KO mice are GH resistant, which may alter neurotransmission and the levels of other hormones, thereby delaying brain aging and cognitive decline 30 . We examined the hypothalamus, hippocampus, and striatum in 4-6 month, 8-10 month, and 20-22 month GHR-KO mice that experience successful aging compared to normal aging littermate control mice by assessing mRNA expression levels of brain markers involved in age and metabolic disorders including inflammatory and glutamatergic markers. Anti-inflamatory markers included IKKβ, NFκB-p50, and NFκB-p65, whereas the pro-inflammatory marker IL-1β was examined. Growth factor markers including IGF-1 and its receptor. Finally, glutamatergic transporters (vesicular Glu transporter (VGLUT) 1, VGLUT3, GLAST, Glu type I transporter (GLT-1)) and receptor subunits (N-methyl D-aspartate receptor subunit 2b (GluN2B) and GluA1) were measured. 
Methods

Animals
RNA purification and PCR analysis
All animals were decapitated under isoflurane anesthetic and their brains were rapidly removed.
The hippocampus, hypothalamus, and striatum were dissected on wet ice and tissue was immediately frozen on dry ice. Samples were stored at -70 °C until RNA extraction. RNA was purified using the miRNeasy Mini Kit (Qiagen ® , Boston, MA, USA) following the manufacturer's protocol for purification of total RNA from animal tissue. The quantity of total RNA was determined using an ND-1000 Spectrophotometer (NanoDrop ® , Wilmington, DE, USA) and complimentary DNA (cDNA) was synthesized from 2 µg of total RNA using a cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) following the manufacturer's protocol.
Real-time polymerase chain reaction (RT-PCR) was performed on individual samples as previously described 39 . Briefly, each reaction contained 12.5 µL iQ SYBR Green Supermix (BioRad, Hercules, CA, USA), 0.4 µL each of backward and forward primer (see Table 1 ), and 2 µL diluted cDNA (3 H2O: 1 cDNA). The reaction included 2 minutes at 94ºC (denaturing), 30 seconds at 62ºC (annealing), and 30 seconds at 72ºC (extension). Β-2-microglobulin was used as the housekeeping gene control, based on prior studies involving altered inflammatory states, and was used to determine relative expression of the mRNA of interest as previously described 39 .
Data analysis
All data were generated from individual mice. Mean and standard error of the mean (SEM) were determined for each group (n = 5-9 mice per group). A Two-way analysis of variance (ANOVA) with a Fisher's least significant difference (LSD) post hoc test was used to determine age-related changes in mRNA levels within genotypes and age-matched alterations between genotypes.
Statistical significance was determined at p < 0.05.
Results
Altered mRNA Expression Levels in the Hippocampus
Inflammatory Markers
We observed significant age-related decreases in IKKβ in the hippocampus of control and GHR-KO mice (F(2,36)=17.28; p<0.0001). In control mice, there was a significant decrease in mRNA expression in 8-10 (p<0.001) and 20-22 month (p<0.0001) mice compared to 4-6 month mice ( Figure 1A ). In the GHR-KO mice, 20-22 month mice were significantly decreased compared to 4-6 (p<0.001) and 8-10 month (p<0.05) mice ( Figure 1A ). There was no difference in IKKβ between age-matched genotypes ( Figure 1A ). There was significant age-related decreases (F(2, 36)=3.782; p=0.0323) and a trend in genotypic differences (F(1,36)=3.712; p=0.0620) and no overall interaction in NFκB-p50 mRNA expression in the hippocampus. NFκB-p50 was decreased in 8-10 month control mice compared to 4-6 month control mice (p<0.05) and in 20-22 month GHR-KO mice compared to 8-10 month GHR-KO mice (p<0.05; Figure 1B ). Additionally, 8-10 month GHR-KO mice had significantly elevated NFκB-p50 mRNA levels compared to agematched controls (p<0.01; Figure 1B ). There were no significant age-or genotype-related changes in NFκB-p65 in the hippocampus ( Figure 1C ). We observed significant age-related alterations in IL-1β mRNA expression in the hippocampus (F(2,33)=4.492; p=0.0188). IL-1β was significantly decreased in 4-6 month GHR-KO mice compared to 8-10 (p<0.01) and 20-22 month (p<0.05) GHR-KO mice ( Figure 1D ) and in 4-6 month old mice when comparing genotypes (p<0.05). There were no age-related changes in IL-1β mRNA expression in the hippocampus of control mice ( Figure 1D ).
Growth Factors
There were no age-or genotype-related changes in IGF-1 in the hippocampus ( Figure 1E ).
However, IGF-1R mRNA expression was significantly decreased with age (F(2,36)=6.568; p=0.0037). 20-22 month control mice expressed less IGF-1R compared to 4-6 (p<0.01) and 8-10 month (p<0.01) control mice ( Figure 1F ). There were no genotype-related changes in IGF-1R in the hippocampus ( Figure 1F ).
Glutamatergic Markers
We observed altered VGLUT1 with age (F(2,38)=8.136; p=0.0011) in the hippocampus. The expression of VGLUT1 was significantly decreased in 8-10 (p<0.01) and 20-22 month (p<0.001) normal control mice compared to 4-6 month mice ( Figure 1G ). There were no age-related changes in GHR-KO mice or genotype-related alterations in VGLUT1 ( Figure 1G ). There was significance difference between genotypes in GLT-1 mRNA expression in the hippocampus (F(1,37)=7.481; p=0.0095). GLT-1 was significantly (p<0.05) elevated in 8-10 month GHR-KO mice compared to age-matched control mice ( Figure 1I ). There were no age-associated alterations in GLT-1 expression levels ( Figure 1I ). GluN2B was significantly altered with age (F(2,39)=5.970; p=0.0055) in the hippocampus, with 8-10 (p<0.05) and 20-22 month olds (p<0.01) being significantly decreased in normal aging control mice ( Figure 1K ). There were no age-related changes in GHR-KO mice or genotype-related alterations in GluN2B ( Figure 1K ). GluA1 was also significantly altered with age (F(2,34)=6.080; p=0.0055) with 20-22 month control and GHR-KO mice being significantly decreased (p<0.05 and p<0.01, respectively) compared to 4-6 month mice of the same genotype ( Figure 1L ). No genotype-associated changes were observed in GluA1 levels ( Figure 1L ). No age-or genotype-related changes were observed in VGLUT3 or GLAST ( Figure 1H and 1J, respectively).
Altered mRNA Expression Levels in the Hypothalamus
Inflammatory Markers
We observed significant age-related decreases in IKKβ in the hypothalamus (F(2.39)=7.003;
p=0.0025) with 20-22 month control mice having significantly lower IKKβ mRNA expression compared to 4-6 (p<0.001) and 8-10 month (p<0.05) mice of the same genotype ( Figure 2A ).
There were no significant changes related to age in GHR-KO mice or between genotypes in the hypothalamus ( Figure 2A ). There were no significant age-related changes in NFκB-p50 in the hypothalamus of control or GHR-KO mice ( Figure 2B ). However, NFκB-p50 was significantly elevated (F(1,39)=13.31; p=0.0008) in 8-10 and 20-22 month (both p<0.01) GHR-KO mice compared to age-matched controls ( Figure 2B ). NFκB-p65 expression levels were altered in regards to age (F(2,37)=3.624; p=0.0365) and genotype (F(1,37)=5.590; p=0.0234), but with no overall interaction (F(2,37)=1.784; p=0.1821). NFκB-p65 was decreased in the hypothalamus of 8-10 month control mice compared to 4-6 month control mice (p<0.01; Figure 2C ). Additionally, NFκB-p65 was elevated in 20-22 month GHR-KO mice compared to age-matched controls (p<0.05; Figure 2C ). There were no significant age-related changes in IL-1β in the hypothalamus of control or GHR-KO mice ( Figure 2D ). However, IL-1β was significantly decreased (F(1,37)=14.51; p=0.0005) in 4-6 and 8-10 month (both p<0.05) GHR-KO mice compared to agematched controls ( Figure 2D ).
Growth Factors
There were no age-or genotype-related changes in IGF-1 in the hypothalamus ( Figure 2E ). There were also no age-related changes in IGF-1R in the hypothalamus ( Figure 2F ). However, IGF-1R mRNA expression was significantly altered in relation to genotype (F(1,39)=4.873; p=0.0332).
20-22 month old GHR-KO mice expressed more IGF-1R compared to age-matched control mice (p<0.01; Figure 2F ).
Glutamatergic Markers
We observe altered age-(F(2,34)=5.451; p=0.0088) and genotype-(F(1.34)=8.598; p=0.0060) related changes in VGLUT1 in the hypothalamus, with no significant interaction ( Figure 2G ). 8-10 month GHR-KO mice had significantly elevated VGLUT1 expression when compared to 4-6 (p<0.05) and 20-22 month (p<0.001) GHR-KO mice ( Figure 2G ). Additionally, VGLUT1 in 8-10 month GHR-KO mice was significantly increased compared to age-matched control mice (p<0.001; Figure 2G ). There was a significant difference in GLAST expression in the hypothalamus between genotypes (F(1,39)=5.545; p=0.0237) with 20-22 month GHR-KO mice being significantly increased compared to age-matched control mice (p<0.05; Figure 2J ). No agerelated differences were observed in GLAST expression levels. Finally, there were age-(F(2,38)=4.107; p=0.0243) and genotype-(F(1,38)=12.44; p=0.0011) related changes in GluA1 expression levels in the hypothalamus with no significant interaction ( Figure 2L ). There was a significant decrease in GluA1 expression in 20-22 month control mice compared to 4-6 month control mice (p<0.01), but not in GHR-KO mice ( Figure 2L ). Additionally, both 8-10 (p<0.05) and 20-22 month old GHR-KO (p<0.01) mice had elevated GluA1 expression in the hypothalamus compared to age-matched controls ( Figure 2L ). There were no age-or genotype-related changes in expression levels of VGLUT3, GLT-1, or GluN2B in the hypothalamus ( Figures 2H, 2I , and 2K, respectively).
Altered mRNA Expression Levels in the Striatum
Inflammatory Markers
There were no age-or genotype-related changes in mRNA expression levels in any of the antiinflammatory markers examined ( Figures 3A, 3B , and 3C, respectively). However, we observed genotype-related changes in pro-inflammatory IL-1β (F(1,29)=4.265; p=0.0480), which was significantly decreased in 8-10 month GHR-KO mice compared to age matched controls (p<0.05; Figure 3D ).
Growth Factors
As was the case in the hippocampus and hypothalamus, we did not observe any significant differences in IGF-1 mRNA expression levels in the striatum ( Figure 3E ). However, we did observe age-related changes in IGF-1R expression in the striatum (F(2,37)=7.834; p=0.0015).
IGF-1R expression was significantly decreased in 20-22 month mice compared to both 4-6 and 8-10 month old mice for both genotypes (GHR-KO: p<0.01 and p<0.05, respectively; control:
p<0.05 and p<0.05, respectively).
Glutamatergic Markers
We observed age-(F(2,28)=18.92; p<0.0001) and genotype-(F(1,28)=8.343 and p<0.0074) associated changes in VGLUT1 mRNA expression levels in the striatum. VGLUT1 in 8-10 month control mice was significantly elevated compared to 4-6 (p<0.0001) and 20-22 month (p<0.0001) control mice and compared to age-matched GHR-KO mice (p<0.0001; Figure 3G ). There was a significant effect of age (F(2,31)=5.356; p=0.0100) on GLT-1 expression in the striatum with levels in 20-22 month control mice being significantly elevated compared to 4-6 (p<0.05) and 8-10 month (p<0.001) mice of the same genotype ( Figure 3I ). Additionally, we observed age-related changes in GluA1 expression in the striatum (F(2,34)=13.28; p<0.0001). GluA1 levels in 20-22 month control mice were significantly elevated compared to 8-10 month control mice (p<0.05; Figure 3L ). GluA1 expression was also elevated in 20-22 month GHR-KO mice compared to 4-6 (p<0.0001) and 8-10 month old (p<0.0001) GHR-KO mice. There were no significant changes in striatal VGLUT3, GLAST, or GluN2B ( Figures 3H, 3J , and 3K, respectively).
Discussion
Neurobiological components and functions have been extensively examined as they relate to aging diseases and disorders. However, few studies have examined the brain in relation to increased healthspan. and little is known about the neurological factors that might influence cognitive function and how they change with aging. However, Masser and colleagues recently reported on an existing correlation between mRNA expression and cognitive function in rats 40 . The aim of this study was to determine if glutamatergic and inflammatory markers, that are known to be altered in aging and/or age-related diseases and disorders, are preserved in GHR-KO mice that experience successful aging. The majority of age-and genotype-related differences were detected in the hippocampus and hypothalamus of the 20-22 month old mice.
We focused on the NFκB family due to its involvement in learning and synaptic plasticity [41] [42] [43] , which is often affected in aging and age-related disorders. Inactive NFκB is usually expressed with three subunits (IKKβ, p50, and p65). In the active state, IKKβ is ubiquinated, p50 and p65 form dimers and bind to NFκB sites in the promoter region of target genes, thereby activating transcription and/or expression. In the hippocampus, we observed significantly elevated NFκB-p50 mRNA levels in 8-10 month old GHR-KO mice compared to littermate controls, but no other genotype-associated changes in IKKβ, NFκB-p50, or NFκB-p65 at any of the ages studied. This may be indicative of a mechanism whereby NFκB-p50 is involved in the sustained cognition in GHR-KO mice. In the hippocampus, NFκB p65/p50 heterodimers are localized to the cytoplasm and synapses and are activated by excitation, such as that produced by glutamate [43] [44] [45] .
Interestingly, Boersma and colleagues 46 postulate that transcriptional regulation via NFκB is required for the induction of changes in excitatory synapses and spine density, but not for maintenance. Furthermore, deletion of either the NFκB-p50 or NFκB-p65 gene in mice has been associated with decreased cognition 43, 46, 47 .
We also evaluated a pro-inflammatory cytokine, IL-1β, due to its link to glutamatergic neurotransmission. Glu is the predominant excitatory neurotransmitter in the mammalian central nervous system and under normal conditions, it plays an important role in several brain functions including learning and memory, energy expenditure, and insulin-glucose homeostasis, and other higher-level functions 7 . However, when Glu is present in excess, it can lead to neuroinflammation, excitotoxicity, and cell death. We observed significantly reduced IL-1β mRNA in 4/6 and/ or 8-10 month GHR-KO mice compared to normal littermates in all three brain areas examined. This elevated IL-1β mRNA expression in the brains of control mice may lead to an increase in extracellular Glu by increasing the velocity of the cystine-Glu exchanger (xCT) as has been observed by Hewett's group
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. We also observed significantly decreased GLT-1 expression in the hippocampus of middle-aged control mice compared to age-matched GHR-KO mice.
Interestingly, previous studies have shown that elevated IL-1β decreases Glu uptake via decreasing the surface expression of GLT-1 on astrocytes, possibly leading to increased extracellular Glu 48 .
Taken together, these data provides a mechanism whereby decreased IL-1β early in life could provide protection from Glu-related cognitive decline later in life. Finally, we examined glutamatergic markers in the brain of GHR-KO mice. It is well known that elevated Glu levels in the hippocampus can lead to excitotoxicity, neurodegeneration, and decreased cognition associated with aging and age-related disorders. This elevation could be due to an increase in Glu release through increased packaging or stimulated release, a decrease in Glu clearance (fewer transporters), or a combination of the two. GLT-1 was significantly decreased in the hippocampus in 8-10 month control mice compared to age-matched GHR-KO mice. However, sustained Glu neurotransmission in the hippocampus throughout life may be required for cognitive retention in old age. In support of this, hippocampal mRNA levels of VGLUT3 and GluN2B decreased with age in control mice, but sustain levels in GHR-KO mice, contrary to what was previously reported on GluN1 mRNA levels in the hippocampus of GHR-KO mice 53 . In the hypothalamus, mRNA levels of GluA1 was significantly decreased with age in control mice, sustained in GHR-KO mice, and significantly elevated in 20-22 month GHR-KO mice when comparing the two genotypes, suggesting that Glu may play a role in insulin-glucose homeostasis.
Additionally, VGLUT1 expression was significantly elevated in GHR-KO 8-10 month hypothalamus, which coincided with decreased VGLUT1 levels in GHR-KO striatum at the same age. In the striatum, we observed age-related changes in VGLUT1, GLT-1, and GluA1 in normal aging mice. In GHR-KO mice the only significant change with age was observed in mRNA expression levels of GluA1. Additionally, when comparing the two genotypes, mRNA levels of VGLUT1 in the striatum were decreased in 8-10 month GHR-KO mice. Taken together, our results support that sustained glutamatergic markers throughout aging in the hippocampus, hypothalamus, and striatum of GHR-KO mice may play a role in the retained cognition, energy expenditure, insulin-glucose homeostasis, the sleep-wake cycle, and neuroendocrine output of the pituitary gland previously observed in these mice.
In conclusion, we observed age-related alterations in neuroinflammation, growth factor, and glutamatergic markers in normal aging mice that were rescued in GHR-KO mice. Of major importance was the observed decreased IL-1β expression in all three brain areas in 4-6 and/or 8-10 month GHR-KO mice, sustained glutamatergic neurotransmission/regulation, and sustained IGF-1R expression in the hippocampus and hypothalamus in 20-22 month GHR-KO mice. These data support the importance of brain inflammation in early life and maintained homeostasis of the glutamatergic, growth factor, and inflammatory systems in successful aging. Future studies will address how these mRNA expression levels relate to protein levels. 
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